← 프로그램 목록
ADCPhase 1Recruiting

Parsaclisib

Incyte Corporation

비교

Parsaclisib(Incyte Corporation)은 Ann Arbor Stage II Diffuse Large B-Cell 표적 ADC로, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma; Ann Arbor Stage II Follicular Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeting the classical complement pathway. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 88.1% (ClinicalTrials.gov NCT04434937). 차별점: novel, potent, highly selective, next-generation oral inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ) for pa.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 13일 (1일 전)PK/독성 2026년 7월 13일 (1일 전)

Ann Arbor Stage II Diffuse Large B-Cell

Ann Arbor Stage II Diffuse Large B-Cell Lymphoma; Ann Arbor Stage II Follicular Lymphoma

Recruiting

Technology

구조모아 · StructureMoa에서 구조 검색

bispecific agents (ianalumab, obexelimab, povetacicept), neonatal Fc r

novel, potent, highly selective, next-generation oral inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ) for pa

Mechanism of Action

targeting the classical complement pathway

apoptosis (navitoclax, navtemdalin), signaling pathways (parsaclisib), bone marrow fibrosis (AVID200, PRM-151), in addition to ot

biomarkers and additional clinical features are being sought to assess new agents and tailor emerging therapi

downregulation in inflammatory gene expression consistent with PI3Kδ pathway inhibition

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 34건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 3 · Phase 2 · Phase 1 · Phase 1, Phase 2
  • Status: Terminated · Completed · Active, not recruiting
  • 주요 endpoint: Percentage of Participants Achieving ≥35% Reduction in Spleen Volume From Baseline to Week 24 as Measured by Magnetic Resonance Imaging [MRI] (or Computed Tomography [CT] Scan in Applicable Participants) · Percentage of Participants Who Had a ≥50% Reduction in Total Symptom Score (TSS) From Baseline to Week 24 as Measured by the Myelofibrosis Symptom Assessment Form v4.0 (MFSAF v4.0) Diary · Change in TSS From Baseline to Week 24 as Measured by the MFSAF v4.0 Diary · Time to the First ≥50% Reduction in TSS as Measured by the MFSAF v4.0 Diary · Overall Survival
  • 등록된 결과: ORR 88.1%
  • PFS: NA
  • 핵심: The purpose of this study is to assess the efficacy and safety of parsaclisib in Japanese participants with relapsed or …

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Parsaclisib은 어떤 치료제인가요?
Parsaclisib(Incyte Corporation)은 Ann Arbor Stage II Diffuse Large B-Cell 표적 ADC로, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma; Ann Arbor Stage II Follicular Lymphoma 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Parsaclisib의 임상 단계는?
Parsaclisib의 현재 단계는 Phase 1입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.